A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating γ-retroviral vectors using targeted integration

Gene Therapy

Volumn 17, Issue 2, 2010, Pages 272-280

  Loew, R ^a   Meyer, Y ^a   Kuehlcke, K ^a   Gama Norton, L ^b,f   Wirth, D ^b   Hauser, H ^b   Stein, S ^c   Grez, M ^c   Thornhill, S ^d   Thrasher, A ^d   Baum, C ^e   Schambach, A ^e  

^a BIONTECH AG   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

G retroviral vectors; SIN vector production; Stable packaging lines

Indexed keywords

GENOMIC RNA; NEOMYCIN; RETROVIRUS VECTOR; SELF INACTIVATING GAMMA RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ARTICLE; BIOTECHNOLOGICAL PRODUCTION; CELL STRAIN; CELL STRAIN PG13; CLONING VECTOR; CONTROLLED STUDY; DNA INTEGRATION; GENE CASSETTE; GENE LOCUS; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; MARKER GENE; PRIORITY JOURNAL; PROMOTER REGION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS INACTIVATION;

CELL LINE; DNA NUCLEOTIDYLTRANSFERASES; FEASIBILITY STUDIES; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; RETROVIRIDAE; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 76749155354     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.134     Document Type: Article

References (42)

1. Cavazzana-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. Nature 2004; 427: 779-781.
2. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. New Engl J Med 2002; 346: 1185-1193. (Pubitemid 34984579)
3. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
4. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-458.
5. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
6. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New Engl J Med 2003; 348: 255-256.
7. Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718-725.
8. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696.
9. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119: 964-975.
10. Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-2553.
11. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
12. Negre D, Cosset FL. Vectors derived from simian immunodeficiency virus (SIV). Biochimie 2002; 84: 1161-1171. (Pubitemid 36253742)
13. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194-3198.
14. Schambach A, Wodrich H, Hildinger M, Bohne J, Krausslich HG, Baum C. Context dependence of different modules for post-transcriptional enhancement of gene expression from retroviral vectors. Mol Ther 2000; 2: 435-445.
15. Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 2006; 13: 391-400.
16. Schambach A, Swaney WP, Loo JC. Design and production of retro-and lentiviral vectors for gene expression in hematopoietic cells. Methods Mol Biol 2009; 506: 191-205.
17. Bode J, Schlake T, Iber M, Schubeler D, Seibler J, Snezhkov E et al. The transgeneticist's toolbox: novel methods for the targeted modification of eukaryotic genomes. Biol Chem 2000; 381: 801-813.
18. Wirth D, Gama-Norton L, Riemer P, Sandhu U, Schucht R, Hauser H. Road to precision: recombinase-based targeting technologies for genome engineering. Curr Opin Biotechnol 2007; 18: 411-419.
19. Schucht R, Coroadinha AS, Zanta-Boussif MA, Verhoeyen E, Carrondo MJ, Hauser H et al. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. Mol Ther 2006; 14: 285-292.
20. Coroadinha AS, Schucht R, Gama-Norton L, Wirth D, Hauser H, Carrondo MJ. The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange. J Biotechnol 2006; 124: 457-468.
21. Verhoeyen E, Hauser H, Wirth D. Evaluation of retroviral vector design in defined chromosomal loci by Flp-mediated cassette replacement. Hum Gene Ther 2001; 12: 933-944.
22. Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65: 2220-2224.
23. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187.
24. Schlake T, Bode J. Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci. Biochemistry 1994; 33: 12746-12751.
25. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733-6737.
26. Schambach A, Mueller D, Galla M, Verstegen MM, Wagemaker G, Loew R et al. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Therapy 2006; 13: 1524-1533.
27. Armentano D, Yu SF, Kantoff PW, von Ruden T, Anderson WF, Gilboa E. Effect of internal viral sequences on the utility of retroviral vectors. J Virol 1987; 61: 1647-1650.
28. Adam MA, Miller AD. Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions. J Virol 1988; 62: 3802-3806.
29. Schambach A, Galla M, Maetzig T, Loew R, Baum C. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 2007; 15: 1167-1173.
30. Chung JH, Bell AC, Felsenfeld G. Characterization of the chicken beta-globin insulator. Proc Natl Acad Sci USA 1997; 94: 575-580.
31. Moreno-Carranza B, Gentsch M, Stein S, Schambach A, Santilli G, Rudolf E et al. Transgene optimization significantly improves SIN vector titers, gp91(phox) expression and reconstitution of superoxide production in X-CGD cells. Gene Therapy 2009; 16: 111-118.
32. Thornhill SI, Schambach A, Howe SJ, Ulaganathan M, Grassman E, Williams D et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 2008; 16: 590-598.
33. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
34. Lindemann D, Patriquin E, Feng S, Mulligan RC. Versatile retrovirus vector systems for regulated gene expression in vitro and in vivo. Mol Med 1997; 3: 466-476.
35. Bueler H, Mulligan RC. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol Med 1996; 2: 545-555.
36. Freas-Lutz DL, Correll PH, Dougherty SF, Xu L, Pluznik DH, Karlsson S. Expression of human glucocerebrosidase in murine macrophages: identification of efficient retroviral vectors. Exp Hematol 1994; 22: 857-865.
37. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
38. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23: 628-633.
39. Pietschmann T, Heinkelein M, Heldmann M, Zentgraf H, Rethwilm A, Lindemann D. Foamy virus capsids require the cognate envelope protein for particle export. J Virol 1999; 73: 2613-2621.
40. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
41. Loew R, Rausch T. Sensitive, nonradioactive northern blots using alkaline transfer of total RNA and PCR-amplified biotinylated probes. Biotechniques 1994; 17: 1026-1028, 1030.
42. Gama-Norton L, Herrmann S, Schucht R, Coroadinha A, Loew R, Alves P et al. Retroviral vector performance upon integration in to defined chromosomal loci of modular packaging cell lines. Hum Gene Ther (submitted).